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    BACKGROUND  
HMGB1 IN HUMAN DISEASE LIKE CANCER AND 
DIABETES MELLITUS. 
 
The high mobility group box 1 (HMGB1) protein is an abundant non-
histone component of chromatin, well known for its two DNA 
binding domains, HMG box A and HMG box B. The main ability of 
the HMGB1 protein is to recognize and bind with high affinity to  
DNA. The HMGB1 protein functions have been correlated to cancer 
progression, in fact an elevated expression of HMGB1 occurred in 
certain types of primary tumors, including melanoma and in the 
majority of cases HMGB1 is associated with invasion and 
metastasis. The protein was proposed to be directly involved in 
tumor cell metastasis through its ability to promote cell migration, 
modulate the adhesive properties of cells and modify components 
of the extracellular matrix (Todorova et al. 2012). 
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We know for sure that the main signalling pathway is activated 
through the interaction with a Receptor for Advanced Glycation 
End products (RAGE). 
RAGE is a member of the immunoglobulin superfamily of cell 
surface molecules and consists of three extracellular 
immunoglobulin domains V, C1 and C2, a transmembrane helix and a 
short cytosolic tail (Marion et al. 1999).  
 RAGE is expressed in a wide range of tissues such as lung, heart, 
kidney, brain, skeletal muscles and in different types of cells 
including endothelial cells, macrophages/monocytes, neutrophils, 
and lymphocytes. With AGEs interaction, RAGE mediate the 
effects of its other extracellular ligands (extracellular high 
mobility group box-1 (HMGB1), S100 family of calcium binding 
proteins among many others). Although a large number of advanced 
glycation end products have been identified in humans, AGE/RAGE 
signaling ex-vivo is mostly studied using the AGEs such as AGE-
modified albumin. 
The discovery that RAGE bound “amphoterin” or HMGB1 suggested 
for the first time roles for RAGE in cellular migration and 
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invasiveness, initially in the context of neurite outgrowth 
(Ramasamy et al. 2009).  
RAGE interacts with various structurally different ligands, 
including advanced glycation end products (AGEs), amyloid β peptide 
(Aβ), transthyretin, amphoterin and members of the S100 protein 
family (S100 proteins regulate intracellular processes such as cell 
growth and motility, cell cycle regulation, transcription and 
differentiation) (Sárkány et al. 2011).  
 
FIGURE 1: Associations of sRAGE (RAGE extracellular region, 
soluble protein, may contribute to the removal/neutralization of 
circulating ligands) and RAGE with different aspects of 
metabolic, vascular and autoimmune disease. 
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It is speculated, that the soluble forms of RAGE might counteract 
inflammatory reflexes triggered by RAGE ligands such as AGEs, 
S100 proteins and HMGB1 (Humpert et al. 2007).  
 
FIGURE 2: Receptor of advanced glycation end products 
(RAGE)-mediated signal transduction. AGE, advanced glycation 
end product; HMGB1, high-mobility group box protein 1; IκB, 
inhibitor of kappa B; IKK, inhibitor of kappa B kinase; JAK, 
Janus kinase; JNK, c-jun N-terminal kinase; NF-κB, nuclear 
factor kappa B; ROS, reactive oxygen species. 
 
 
 8 
HMGB1 is able to activate other cells involved in immune response 
or inflammatory reactions, thus acting as a cytokine itself. The 
protein can also be passively released by damaged or necrotic cells, 
leading to inflammation. A number of post-translational 
modifications including acetylation, phosphorylation, methylation 
and poly(ADP)-ribosylation have been suggested to direct HMGB1 to 
the secretory pathway (Todorova et al. 2012).  
All these considerations indicate that HMGB1 is a very important 
mediator of inflammatory response, with several mechanisms of 
action not yet completely elucidated.  
 
DIABETES MELLITUS 
 
Diabetes mellitus (DM) is a metabolic disease characterized by 
hyperglycaemia resulting from defects in insulin secretion, insulin 
action, or both. The chronic hyperglycaemia of diabetes is 
associated with long-term damage, dysfunction, and failure of 
various organs, especially the eyes, kidneys, nerves, heart, skin and 
blood vessels. Several pathogenic processes are involved in the 
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development of diabetes e.g. autoimmune destruction of the β-cells 
of the pancreas with consequent insulin deficiency, or other 
abnormalities that result in resistance to insulin action. The basis 
of the abnormalities in carbohydrate, fat, and protein metabolism in 
diabetes is deficient action of insulin on target tissues.  
Impairment of insulin secretion and defects in insulin action 
frequently coexist in the same patient, and it is often unclear which 
abnormality, if either alone, is the primary cause of the 
hyperglycaemia. 
DM is characterized by the onset of acute and long-term 
complications, the latter including retinopathy with potential loss of 
vision; nephropathy leading to renal failure; peripheral neuropathy 
with risk of foot ulcers and amputations; autonomic neuropathy 
causing gastrointestinal, genitourinary and cardiovascular symptoms 
and sexual dysfunctions. Moreover patients with diabetes have an 
increased incidence of atherosclerosis and cardiovascular diseases. 
(American Diabetes Association 2012). 
There are two types of diabetes:  
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- Type 1 diabetes (T1D), is an autoimmune disorder 
characterized by the specific destruction of the insulin 
secreting beta cells of the pancreatic islets by a certain 
population of autoreactive immune cells. About 10% of the 
total number of DM patients suffer for this type of diabetes 
which is also called juvenile diabetes, for the age of onset, 
and insulin-dependent, due to the pathogenetic mechanisms. 
The therapy is mainly related to the insulin replacement. 
Insulin is a hormone that is needed to convert sugar, 
starches and other food into energy needed for daily life. 
With the help of insulin therapy and other treatments, even 
young children with type 1 diabetes can learn to manage their 
condition and live long, healthy, happy lives 
(http://www.diabetes.org/diabetes-basics/type-1/). 
- Type 2 diabetes (T2D), the cause is a combination of 
resistance to insulin action and an inadequate compensatory 
insulin secretory response. A degree of hyperglycaemia 
sufficient to cause pathologic and functional changes in 
various target tissues, but without clinical symptoms, may be 
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present for a long period of time before diabetes is 
detected. During this asymptomatic period, it is possible to 
demonstrate an abnormality in carbohydrate metabolism by 
measurement of plasma glucose in the fasting state or after 
a challenge with an oral glucose load.  
The degree of hyperglycaemia may change over time, depending on 
the extent of the underlying disease process. The same disease 
process can cause impaired fasting glucose (IFG) and/or impaired 
glucose tolerance (IGT) without fulfilling the criteria for the 
diagnosis of diabetes. In some individuals with DM, adequate 
glycemic control can be achieved with diet, weight reduction, 
exercise, and/or oral glucose-lowering agents. These individuals 
therefore do not require insulin. Other individuals who have some 
residual insulin secretion but require exogenous insulin for adequate 
glycemic control can survive without it. Individuals with extensive 
β-cell destruction and therefore no residual insulin secretion 
require insulin for survival.  
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Thus, the degree of hyperglycaemia reflects the severity of the 
underlying metabolic process and its treatment more than the 
nature of the process itself. 
  
PATHOGENETIC MECHANISMS OF DIABETIC 
COMPLICATIONS  
 
During diabetes, hyperglycaemia affects the cells of all tissues but 
the detrimental effects of this metabolic disorder can be 
selectively observed in the insulin-independent tissues in which the 
glucose uptake into the cells does not require the action of insulin 
leading to a high intracellular concentration of the sugar.  
In the past decades, several studies demonstrated that the 
pathogenetic cascade of diabetes-induced complications is related 
to the metabolic consequences of excess glucose disposal, either 
through repeated acute changes in cellular glucose metabolism, or 
through the long-term accumulation of altered products.  
In detail, acute hyperglycaemia is characterized by an increase of 
biomarkers of oxidative stress and cytokine secretion, which are 
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concomitant with a decreased activity of antioxidant systems 
induced by glucose intake (Vlassara et al. 2002).  
Chronic exposure to high glucose is essentially linked to the 
formation of glycated biomolecules and the progressive 
accumulation of Advanced Glycation End-products (AGEs) through 
the augmentation of the entity of the chemical (non enzymatic) 
reaction of reducing sugars with amino groups. The Maillard 
reaction is also known as glycation, (FIGURE 3) which leads to the 
formation of early, intermediate (Schiff base, Amadori) and 
advanced glycation products (Ramasamy et al. 2011; Pricci et al. 
2000). 
Further, the interaction between AGEs and receptor for AGEs 
(RAGE) also cause inflammation and oxidative stress (Nagai et al. 
2012). 
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FIGURE 3: The Maillard reaction occurs in three main steps: 
Initial step is formation of N glycoside the immonium ion is 
formed and then isomerize, this reaction is called Amadori 
rearrangement and forms a compound called ketosamine. 
 
 Finally, this pathway has been demonstrated to lead to oxidative 
stress and pro-inflammatory signalling implicated in endothelium 
dysfunction, arterial stiffening, and microvascular complications 
(Vlassara et al. 2002; Stitt et al. 2003; Scivittaro et al. 
2000).  
Recent studies have demonstrated that the non-enzymatic glycation 
is not exclusively linked to the high availability of glucose, but 
numerous intermediate metabolites, such as α-ossoaldehydes (for 
example the methylglyoxal), generated during glycolysis, the polyol 
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pathway, or the autoxidation of carbohydrates (glyoxal), may 
participate in the non-enzymatic glycation (FIGURE 4).  
The α-ossoaldehydes, for instance, create AGE surprisingly quickly, 
unlike the Maillard reaction, which is significantly slower (Leto et 
al. 2001).  
 
FIGURE 4: Pathway of intermediated aldehyde generation. 
 
The predominant route in AGE-products formation may depend on 
many variables, including the type of tissue, the species, the age of 
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the organism and diet, as well as those variables that induce 
oxidative stress. 
In diabetic conditions a metabolic anomalies puts the oxidative 
stress as the central mechanism (acute and in chronic exposure to 
high glucose) leading to the cross-connection of all these metabolic 
pathways (Nishikawa et al. 2000; Brownlee et al. 2001). 
In fact, High Glucose-dependent metabolic alterations have been 
demonstrated to lead to an imbalance in several cytokines and 
signalling molecules, depicting a chronic low-grade inflammation 
pattern, observed in diabetes-affected tissues. In fact the 
damaging effects of hyperglycaemia affect mainly certain cell 
types that (a) are unable to maintain their intracellular glucose 
concentration in hyperglycaemic conditions, and particularly cell 
types involved in diabetic complications (e.g. endothelials and 
neurons) and (b) generate high Reactive Oxygen Species (ROS) 
levels and induce a huge oxidative stress implicated in glycation, 
AGEs formation, and AGE=RAGE interactions (Negre-Salvayre et 
al. 2009).  
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In summary, the metabolic alterations induced by high glucose are 
time-dependent but also strictly interrelated, thus making difficult 
to separate a single pathway responsible to the pathogenesis of 
diabetic complications.  
Regarding the mechanisms of eye diabetic complications, many 
studies examined the mechanisms underlying vasculopathy and 
found that all the metabolic alterations listed below are present 
and lead to vessel alterations and subsequent neo-angiogenesis, 
justifying the different progressive phases of DR (Diabetic 
retinopathy). On the contrary, little is known about the metabolic 
aspects of excess glucose disposal in neuroglial compartment. 
Another very interesting aspect is the observation that 
hyperglycaemic diabetic mice show an impaired angiogenic response 
(Facchiano et al. 2002 and 2006) likely due to glycation of basic 
FGF, one of the most potent angiogenic factors, or of other key 
factors. These studies suggested that the angiogenesis dys-
regulation (a key event both in cancer and in DM complications) may 
be directly related to hyperglycaemia and AGE-products 
accumulation. 
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THE ROLE OF HMGB1 IN CANCER 
 
DM has been recognized as a key factor contributing to the 
development of solid organ malignancies including liver, pancreas, 
colorectal, breast, endometrial, uterine, and bladder. The two 
cancers showing the strongest association to T2D are those 
involving liver and pancreas. Many studies demonstrated increased 
cancer risk and mortality among individuals with T2D, especially 
those with poorly controlled T2D based on fasting serum glucose 
levels. A recent meta-analysis of 23 articles indicated a 41% 
increase in cancer mortality related to endometrial, breast, and 
colorectal cancer in patients with pre-existing diabetes as 
compared to normoglycemic individuals (Grace et al. 2011).  
These studies suggest that the study of pro-inflammatory signals 
related to impaired glucose controls and AGE-products 
accumulation, likely involving a key role of the AGE-RAGE-HMGB1 
axis, is a very interesting and fascinating field of study. Therefore 
it represents one of the main focus of this PhD. Thesis. 
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HMGB1 STRUCTURE, MODIFICATION AND 
EXPRESSION 
 
High-mobility group box protein 1 (HMGB1) belongs to HMG family 
that are typically 25 to 30 kDa molecular weight proteins. The 
superfamily consist of 3 families: HMGA, HMGB and HMGN.  
The HMGB family has three domains: 
- HMG boxes A and boxes B (~75 amino acids); 
- C-terminal domain is highly negatively charged (glutamate and 
aspartate residues) (Agresti et al. 2003) (FIGURE 5). 
HMGB1 is a highly conserved nuclear protein that is a prototype for 
a unique class of pro-inflammatory mediators called  
ALARMINS. As a group, alarmins display distinct intracellular and 
extracellular activities, with potent stimulation of the innate 
immune system as their cardinal feature. 
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Amino acid composition of HMGB1:  
1             11              21               31              41 
MGKGDPKKPR GKMSSYAFFV QTCREEHKKK HPDASVNFSE FSKKCSERWK 
TMSAKEKGKF EDMAKADKAR YEREMKTYIP PKGETKKKFK DPNAPKRPPS 
AFFLFCSEYR PKIKGEHPGL SIGDVAKKLG EMWNNTAADD KQPYEKKAAK 
LKEKYEKDIA AYRAKGKPDA AKKGVVKAEK SKKKKEEEED EEDEEDEEEE 
EDEEDEDEEE DDDDE 
 
FIGURE 5: Structures of HMGB1 protein domains. 
 
While the intracellular functions of alarmins vary, in their 
extracellular form, they function as pro-inflammatory mediators to 
alert the immune system to tissue damage and to trigger an 
immediate response. A key feature of the biology of alarmins is 
therefore their translocation from inside to outside of the cell.   
Human HMGB1, a 215-amino acid protein, contains three major 
functional domains: the A box, the B box, and the C-terminal acidic 
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tail (C tail). Structure-function analyses reveal that the pro-
inflammatory cytokine inducing capacity of HMGB1 localizes to the 
B box, with the most significant cytokine functionality mapping in 
the first 20 amino acid residues of this domain (A box domain). 
HMG boxes A and B are each ~75 amino acids in length, the C-
terminal domain is highly negatively charged, consisting of a 
continuous stretch of glutamate and aspartate residues (Agresti et 
al. 2003). 
 
FIGURE 6: Ribbon model of human HMGB1. 
 
NUCLEAR FUNCTIONS OF HMGB1 
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The HMGB protein contains HMG boxes that bind DNA.  
HMGB1 binds rather weakly to the common B-form variety to DNA 
and hasn't sequence specificity. Instead, it binds with high affinity 
to unusual DNA structure like 4-way junctions and DNA bulges. 
This suggests that HMGB1 might actually function by distorting 
linear DNA into a bent conformation and that it recognized 
molecules that resemble transition state between reagents and 
products. 
The intranuclear concentration of HMGB1 is in micromolar range, 
when HMGB1 concentration will increase the fraction of interacting 
partner molecules. HMGB1 play a role organizing enhanceosomes it 
can modulate the other key factor in transcriptional regulation: 
chromatin remodeling. HMGB1 and other chromatin protein like 
histone H1, can interact with nucleasomes at the entry end exit 
points of DNA. The HMGB1-DNA binding is dynamic and reversible 
in a chaperone mode (Agresti et al., 2003).  
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RECEPTORS ASSOCIATED WITH HMGB1 SIGNALING 
PATHWAYS 
 
 
There are several important receptors have been characterized to 
be implicated in HMGB1 signaling, including the receptor for 
advanced glycation end products (RAGE) and some members of the 
Toll-like family of receptors. The first identified cellular receptor 
for this nuclear protein was the receptor for advanced glycation 
end products (RAGE), which mediates the interactions between 
advanced glycation end product (AGE)–modified proteins and the 
endothelium and other cell types (Hori et al 1995). 
RAGE is a transmembrane protein expressed at low levels in normal 
tissues, but it is up-regulated at sites where its ligands accumulate 
(Chavakis et al. 2004). 
Binding of RAGE by HMGB1 can activate both CDC42/Rac pathway 
and MAPKs-NFκB pathway (Yang et al. 2005).  
These two HMGB1 signaling pathways then through RAGE promotes 
chemotaxis, production of cytokines relevant to NF-κB activation, 
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activation of endothelial cells, maturation and migration of immune 
cells (FIGURE 2). 
There are additional receptor(s) relevant to HMGB1 signaling. 
Consistent with this assumption, follow up studies further 
characterized that toll-like receptors 2 (TLR2) and 4 (TLR4) are 
involved in HMGB1 signaling (Shu Zhang et al 2010) likely through 
Rac1/PI3K/CDC42 pathway and MyD88 dependent NF-κB activation 
pathways. 
                                                                                                            
ADVANCED GLYCATION END PRODUCTS (AGE)  
 
The Advanced Glycation End Products (AGE) are the result of a 
non-enzymatic reaction between reducing sugars and cellular 
components (Proteins, nucleic acid, lipids and other molecules) 
(Munch et al. 1997).  
For example, glucose (or other reducing agents) and a free amino 
group form reversible intermediates of a Schiff base and an 
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Amadori product before a series of reactions that irreversibly 
generate an AGE (Huebschmann et al. 2006). 
But there are more pathways for AGEs formation: 
- the “carbonyl stress” pathway, where oxidation of sugars 
and/or lipids create dicarbonyl intermediate compounds that 
use highly reactive carbonyl groups to bind amino acids and 
form AGEs. 
- Monocytes, macrophages, and dendritic cells secrete the 
nuclear protein amphoterin (similar to HMGB1) to amplify 
inflammation reaction (Huebschmann et al. 2006);  
- neutrophils, monocytes, and macrophages, upon inﬂammatory 
stimulation (reaction non–glucose-dependent) produce 
myeloperoxidase and NADPH oxidase enzymes that induce 
AGE formation by oxidizing amino acids (Huebschmann et al. 
2006). 
- Receptors for AGE (RAGE) when bound to AGEs, associated 
with reactive oxygen species (ROS) generation promote more 
AGEs via the NADPH oxidase pathway (Ramasamy R et al. 
2011; Wautier MP et al. 2001).  
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- The aldose reductase–mediated polyol pathway may directly 
form AGEs via 3-deoxyglucosone AGE intermediates. This 
reaction causes depletion of NADPH and glutathione, and the 
resultant oxidative stress indirectly increases formation of 
AGEs (Huebschmann et al. 2006). 
AGEs can cause extensive cross-linking of proteins its oxidation, 
leading to their deposition, as reported in diabetes and Alzheimer’s 
diseases (Smith et al. 1995; Gella et al. 2009).  
All together these reports indicates that HMGB1’s role in the 
mechanisms of inflammation, apoptosis, angiogenesis, DM and 
cancer, are very important although still poorly known.  
Therefore it is very important to investigate such aspects to 
better understand these pathogenetic mechanisms and possibly 
identify the molecular pathways involved, with the aim to develop 
novel therapeutic strategies for these serious diseases. 
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PhD PROJECT  
AIMS 
 
This study aims to identify proteins that interact with HMGB1, an 
alarmine involved in the metabolic pathways of inflammation, as 
previously described. The research is based, on the achievement of 
the following 3 aims: 
1)  the designation of a proper experimental model;  
2) the development of methods for obtaining a right stimulus (AGE 
accumulation) to study the HMGB1 effects on our models;  
3) the study of the HMGB1-interactome through the use of 
immunoprecipitation methods to be specifically developed coupled 
to SDS-PAGE techniques and mass spectrometry to identify novel 
proteins involved in the interaction with HMGB1. 
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MATERIALS AND METHODS 
IN VITRO GLYCATION 
  
The Bovine Serum Albumin (BSA, Sigma Aldrich. St. Louis, Mo) was 
prepared as previously reported (Pugliese et al. 2008; De Oliveira 
Silva et al. 2008). 
Briefly, 50 mg/ml BSA solution in 0.2 M phosphate buffer, pH 7.8, 
containing antibiotics (10,000 U.I penicillin and 10,000 μg/ml 
streptomycin) and protease inhibitors (1 mM EDTA) was incubated 
with (glycated) or without (non-glycated) 500 mM D-glucose for 8 
weeks at 37 °C under sterile conditions. Glycated-BSA (AGE-BSA) 
and non glycated BSA (BSA) were dialyzed against water for 24 
hours using dialysis membranes (PBI International, MWCO 12,000–
14,000, Milano, Italia), the solution was passed through 22 μm 
filters, assessed for endotoxin content by the Limulus amoebocyte 
lysate assay (SIGMA) and, finally, for AGE levels measurements 
by fluorescence and for protein content by Coomassie Protein 
Assay Kit (Pierce, 3747 N. Meridian Road P.O. Box 117Rockford, IL  
61105).  
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CELL COLTURE AND TREATMENTS 
IN VIVO STUDIES  
 
The experimental activity on animal models was carried out in 
accordance with the “Principles of Laboratory Animal Care” (NIH 
Publication nos. 85–23, revised 1996) and national laws.  
In vivo studies were performed using male Sprague-Dawley rats 
(Harlan Laboratories, Indianapolis) rendered diabetic with 
streptozotocine (STZ) Sigma) a molecule able to induce massive 
destruction of pancreatic β cells. 
The STZ, in buffer solution of 0.1 M sodium-citrate (pH 4.5) 
freshly prepared, was used in an amount equal to 60 mg / Kg of 
weight in animals fasted for about 4 hours and age-matched control 
rats, studied at different times of disease (1, 3, 6, 12 weeks).  
At the end of the experimental procedures, eyes were enucleated 
from each rats and the retina of one eye was isolated for the 
protein studies whereas the other eye was frozen for the tissue 
sectioning. Blood was sampled for the analysis of biochemical 
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parameters of diabetes (fasting glucose, glycated hemoglobin, AGEs 
measurement).  
 
RETINA FROM EYEBULBS  
 
The retinal tissue and eyebulb were fixed in 4% paraformaldehyde 
in PBS, 0.12 M in sucrose for 30 min or overnight. After fixation, 
the samples were rinsed for three times in PBS, with 5% sucrose 
and 0.15 mM CaCl2 and left overnight in sucrose buffer (PBS with 
30% sucrose and 0.15 mM CaCl2). Samples were then embedded in 
Tissue Freezing Medium (Jung, Germany), frozen at −30 °C in 
isopentane and stored at −80 °C. Sections were cut at a Reichert–
Jung Frigocut cryostat, stained with hematoxylin and observed at 
Nikon Optiphot microscope equipped with a video confocal (ViCo) 
System. 
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RETINAL TISSUE CULTURES AND LYSIS  
 
Retinal explants were obtained from 7–8 week-old male Sprague–
Dawley rats. Retinas were dissected according to the protocol 
described by Pinzon-Duarte (Pinzon-Duarte et al 2000).    
Briefly, the eyes were enucleated from rats under deep anaesthesia 
and transferred to a petri dish (Corning Incorporated NY, USA) 
containing ice-cold sterile phosphate-buffered saline (PBS) and 
incised just dorsally to the ora serrata. Cornea and lens were 
removed and the whole retina was carefully dissected from the 
sclera, placed flat onto a PET microporous insert (Transwell, 
Corning Incorporated NY, USA), to allow the tissue being in contact 
with the culture medium at both the apical and basal sides, and 
cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco srl, 
Paisley, Scotland, UK) containing 10% fetal calf serum (FCS, Life 
Technologies, Milan, Italy) and antibiotics, in a tissue culture 
incubator at 37°C, 5% CO2.  
Retinal cells or tissue were preparated as describe in Villa M. PhD 
Thesis.  
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HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS  
 
Human umbilical vein endothelial cells (HUVEC) were from 
(American Type culture Collection, ATCC, Manassas, VA) and were 
cultured and passaged as described (Facchiano et al. 2001) in 
endothelial growth medium (EGM)-2 containing growth factors 
(Hyclone, South Logan, UT), cells were used between passage 3 and 
6. Cells (5x105) were plated in 10 cm Petri dishes or in 6 well plastic 
plates (Corning Incorporated) in the presence of 10% fetal calf 
serum (FCS) containing medium, and after 24 hours growth cells 
were thereafter grown for additional 24-48-72 hours in the 
absence of FCS, but in the presence of AGE or control BSA. At the 
end of this time, cell extracts were produced as described 
(Facchiano et al. 2012).  
The HUVEC were treated a time zero (t0) with 200 µg/ml of Bovine 
Serum Albumine (BSA) with advanced glycation end products (BSA-
AGE) (preparated by incubation with D-Glucose 500 mM for 8 
weeks as above described), BSA 200 µg/ml like a control of BSA-
AGE, Normal Glucose (NG) 5.5 mM corresponding to 
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normoglycaemia, High Glucose (HG) 30mM corresponding to high 
levels of glycemia, Mannitol 30mM (in distilled water, Sigma).  
 
A375 MELANOMA CELLS 
 
The A375 melanoma cells (American Type culture Collection, ATCC, 
Manassas, VA) were propagated under standard culture conditions. 
Cultures were found to be free from Mycoplasma species using the 
Hoechst staining procedure. The A375 melanoma cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, 
South Logan, UT) at pH 7.4, containing FBS (fetal bovine serum) 
(Sigma-Aldrich, St. Louis, MO); at 10%, L-glutamine 2 mM and 
penicillin / streptomycin (100 U / ml) (Invitrogen, Carlsbad, CA) and 
when required in conditions of absence of serum.  
These cells were propagated according to standard culture 
conditions (Facchiano et al. 2012) using 75 cm2 flasks.  
The invasive potential was assessed by in vitro invasion assay as 
described (Albini et al. 1987).  
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The metastatic activity, both spontaneous and experimental, was 
found to be stable over the time of the experimental procedures. 
Cell viability was tested by the Trypan Blue (0.25 %) exclusion test 
at different times of growth. At the end of the treatment, cells 
were photographed and harvested, then cell extracts were 
produced as described (Facchiano et al. 2012). 
 
CELL LYSIS 
 
The process of cell lysis takes place totally in ice using 500 µL of 
lysis buffer and collecting the cells by the aid of a "scraper".  
The sample is maintained for 20 minutes on ice and then subjected 
to centrifugation at 4 ° C for 10 minutes at 13,200 rpm in an 
Eppendorf centrifuge 5415R Centrifuge in order to remove the 
excess of nucleic acids. Then remove the supernatant with a pipette 
tip made of polypropylene from 200 mL and these samples are then 
stored at -80 °C. 
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PROTEIN GEL ELECTROPHORESIS 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) was carried out to analyze proteins based on differences in 
their molecular size, according to a published protocol (Facchiano 
et al. 2010).  
Briefly, our analysis on SDS-PAGE analysis was performed using 
2.4% -18% acrylamide-bisacrylamide gradient. The gels were 
obtained by the polymerization of acrylamide and of 'N, N'-
methylene-bisacrilamide (Bis-acrylamide), which acts by 
crosslinking of linear chains. The polymerization is due to the 
presence of free radicals, provided by the persulphate ammonium 
(APS), stabilized by 'N, N, N', N'-tetra-methylethylene-diamine 
(TEMED). 
Each lane was loaded with 25 µg of total proteins of each sample 
(protein concentration was performed with Bradford methods), 
previously denatured by boiling for 5 min at 100 °C with the 
addition of sample buffer (44 mM Tris-HCl pH 6.8, 2% SDS (w/v), 
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10% Glycerol (v/v), 5% 2-β-mercaptoethanol (v/v) and 0.0125% 
Bromophenol Blue (w/v)), it was run into running buffer (25 mM 
Tris, 250 mM glicina, 0,1% SDS) at 200V constant voltage.  
The gel was then fixed with fixing solution (60% H2O, 30% 
Methanol, 10% Acetic Acid) and then stained with Coomassie 
(Brilliant Blue, acetic acid, methanol, water) (Facchiano et al 
2012).  
 
IMMUMOPRECIPITATION  
 
Immunoprecipitation (IP) is a method that uses the antigen-
antibody interaction principle to isolate a protein that reacts 
specifically with an antibody from mixture of proteins.  
The IP protocol was performed as follows: 
First step (Pre-clearing): 
 the lysate (800 µg of total proteins) was incubated with 
beads (protein A/G GE Healthcare Milwaukee USA previously 
washed with PBS) for 3 hours at room temperature under 
rotation: This can help to reduce the background. 
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The second step: beads-antibody reaction: 
 The antibody (anti-HMGB1 Abcam 79823 Cambridge, UK) was 
incubated with beads over-night at +4°C in rotation according 
to the manufacturer’s instructions.  
The third step: pre-cleared and “activated beads” incubation:  
 The pre-cleared sample was incubated with conjugated beads 
(activated beads) for 3 hours at room temperature under 
rotating conditions. 
Then the tube was centrifugated, the supernatant was 
collected and at the beads (the antibody binding a 
proteins) added with sample buffer then denatured at 
100 °C as above reported. 
After a centrifugation the supernatant was collected (IP) and 
ready to be loaded in the gel. 
The immunoprecipitation was performed by using beads (GE 
Healthcare) pre-incubated for 12 hours at 4 °C in a rotating wheel, 
with anti-human HMGB1 antibody (Abcam) at the following ratio 40 
microliters of Beads : 2 micrograms of antibody . In this way a 
conjugated Bead-IgG complex was abtained. Then the cell lysates 
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were incubated with beads-antibody complex for 12 hours at 4°C. 
Thereafter 3 washes were performed with PBS and the finally 
release of the antibody-antigen complex was achieved by adding 30 
µl sample buffer 4X (β-mercaptanol, SDS 20% glycerol, 1.5M Tris 
pH 6.8, Bromophenol blue) and boiling for 10 min at 100 °C. The 
immunoprecipotated were then analyzed by SDS-PAGE Gradient gel 
(4-15% Biorad, Hercules, CA). 
 
IN GEL DIGESTION 
 
All bands were cut in a piece of the 1 mm3 and puts in a 1.5 ml 
eppendorf tube. The bands were washed, 2 times with 50 mM 
ammonium bicarbonate NH4-HCO3. The next wash was made with 
ammonium bicarbonate/Acetonitrile CH3CN (1:1). The proteins were 
then subjected to reduction by 10 mM DTT, and alkylation 
(alkylating agents that binds the thiol group of cysteines, thereby 
avoiding that can form disulfide bonds) by 55 mM IAM 
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(Iodacedammide) in 50 mM ammonium bicarbonate for 30 minutes 
at room temperature in the dark.  
The bands were shrunk in acetonitrile, dried under vacuum, 
reidrates with trypsin for 45 minutes in the ice and finally digested 
overnight with (Roche Milan, Italy) bovine pancreatic trypsin, a 
protease that is part of the family of serine-protease, which cuts 
specifically at the level of specific residues of arginine (Arg) or 
lysine (Lys). In particular, the trypsin cuts the peptide bond on the 
carboxyl side of Arg and Lys residues, so all the protein fragments 
of a given protein will have at the C-terminal either arginine or 
lysine, with the exception of the C-terminus of the polypeptide 
chain original. 
The tryptic peptide mixtures obtained were analyzed by nanoLC-
MS/MS and Bioworks software (version 3.3, Thermo Electron 
Fremont, CA). 
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WESTERN BLOT ANALYSIS 
 
The proteins separated on gel were transferred by electrophoresis 
at 300 milliAmpere for 30 minutes on a nitrocellulose sheet (0.2 µm, 
Schleicherm & Schuell Whatman Gmbh, Dassel, Germany) in 
transfer buffer (Tris-Glicine). 
To lock the hydrophilic sites that bind nonspecifically, the 
nitrocellulose was saturated at room temperature for 3 h with 
buffer Tween / Tris-buffered Saline (TPBS) containing milk powder 
5%. After washing, the nitrocellulose was incubated with the 
specific primary antibody in a 1.25% solution low fatty acid powder 
milk +TPBS by stirring. 
The primary antibody, polyclonal rabbit anti-HMGB1 (Abcam) was 
used at a concentration of 1:500 and was incubated for 12 h at +4 ° 
C. 3 washes were performed of 15 minutes each in TPBS. The 
nitrocellulose was then incubated with an anti-mouse secondary 
antibody labeled with peroxidase for 1 h at room temperature. 
In order to highlight a reference signal that indicates the amount 
of protein actually present on the nitrocellulose filter was used the 
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mouse monoclonal antibody anti-actin (Oncogen); secondary 
antibody specific incubated for 1 h at room temperature. 
The antigen-antibody reaction was detected by a 
chemiluminescence reaction (Enhanced ChemioLuminescence, 
PIERCE).  
 
MASS SPECTROMETRY ANALYSIS 
 
Peptide mixtures were analyzed by nanoflow reversed-phase liquid 
chromatography tandem mass spectrometry (RP-LC-MS/MS) using 
an HPLC Ultimate 3000 (DIONEX, Sunnyvale, CA U.S.A) connected 
on line with a linear Ion Trap (LTQ, Thermo Electron, San Jose, 
CA). Peptides have been desalted in a trap column (Acclaim PepMap 
100 C18, LC Packings, DIONEX) and then separated in a reverse 
phase column, a 10 cm long fused silica capillary (Silica Tips FS 360-
75-8, New Objective, Woburn, MA, USA), slurry-packed in-house 
with 5 μm, 200 Å pore size C18 resin (Michrom Bio Resources, CA). 
Peptides were eluted using a linear gradient from 96% A (H2O with 
5% acetonitrile and 0.1% formic acid) to 60%B (ACN with 5% H2O 
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and 0.1% formic acid) in 40 min, at 300nl/min flow rate. Analyses 
were performed in positive ion mode and the HV Potential was set 
up around 1.7-1.8kV. Full MS spectra ranging from m/z 400 to 2000 
Da were acquired in the LTQ mass spectrometer operating in a 
data-dependent mode in which each full MS scan was followed by 
five MS/MS scans where the five most abundant molecular ions 
were dynamically selected and fragmented by collision-induced 
dissociation (CID) using a normalized collision energy of 35%. 
Target ions already fragmented were dynamically excluded for 30 
s. Tandem mass spectra were matched against Swissprot Database,  
and through SEQUEST algorithm (Yates et al., 1995) 
incorporated in Bioworks software using fully tryptic cleavage 
constraints with the possibility to have one miss cleavage 
permitted, static carbamidomethylation on cysteine residues and 
methionine oxidation as variable modification. Data were searched 
with 1.5 Da and 1 Da tolerance respectively for precursor and 
fragment ions. A peptide has been considered legitimately 
identified when it achieved cross correlation scores of 1.8 for 
[M+H]1+, 2.5 for [M+2H]2+, 3 for [M+3H]3+, and a peptide 
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probability cut-off for randomized identification of p<0.001. 
Protein and peptide false discovery rate (FDR) has been calculated 
dividing the number of false hits by the number of positive hits 
where the false hits are evaluated using a decoy database directly 
constructed by Bioworks software on the same human database 
used for the target search and adopting the same scoring criteria.  
 
MULTIPLEX ANALYSIS OF CELL EXTRACTS AND 
SUPERNATANTS AFTER AGE EXPOSURE 
 
Samples were collected by cellular lysis and immediately frozen at -
80 °C. Before starting the analysis, samples of such cell extracts 
were thawed at room temperature, then diluted with PBS w/o 
calcium and magnesium (Euroclone, Milan, IT ) and carefully re-
suspended by 7-8 passages through a 26 gauge needle. The protein 
concentration was then measured by Bradford's procedure (Bio-Rad 
protein assay dye reagent concentration, Biorad Laboratories, 
Hercules, CA) and a cuvette spectrophotometer (Kontron, Uvikon 
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860 Instrument Zurich, CH). Samples were then analyzed using the 
Bio-Plex Pro Human Cytokine 27-plex panel (Biorad) developed to 
achieve a quantitative measurement of the following analytes: IL-
1Ra, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-
12p70, IL-13, IL-15, IL-17, TNF-α, IFN-γ, MIP-1α, MIP-1β, eotaxin, 
MCP-1, G-CSF, GM-CSF, basic FGF, VEGF, IP-10, RANTES, and 
PDGFbb. Next, 15 µl of the sample were diluted 4-fold with a Bio-
plex sample diluent according to the manufacturer’s instructions. 
This procedure was carried out using 50 µl of the diluted sample. 
After the incubation with antibodies-activated magnetic beads, 
samples were washed using a Bio-Plex Pro TM Station (Biorad). The 
quantification was carried out on a Bio-plex Array Reader scanner 
for Luminex 100 (Luminex, Biorad) by a Bio-Plex Manager Software 
version 4.1.1.  
Results expressed as picograms/ml were analyzed by a Bio-Plex 
Manager Software version 6. When required, normalization of 
samples was achieved by correcting for the protein concentration 
measured using small aliquots of cells lisate. 
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FPLC CHROMATOGRAPHY 
 
Bovine serum albumine (BSA) or AGE-BSA were analyzed by FPLC 
(Pharmacia, Uppsala, SWEDEN). Proteins were resupended in PBS 
then exposed to sugars as described before. After the incubation, 
aliquotes of 50 micrograms were injected onto a Superose 
Pharmacia column equilibrated with PBS without calcium and 
magnesium. Then elution was carried out with a 0.5 milliliter/min 
flow, at room temperature, and proteins peaks were detected and 
measured under UV recording (optical density at 214 nm). Column 
was calibrated with a mixture of protein molecular weight 
standards (Pharmacia) according to the manufacturer’s instructions. 
 
BIOINFORMATIC ANALYSIS 
 
The bioinformatic analysis of data was performed through DAVID 
portal (http://david.abcc.ncifcrf.gov/). In particular proteins, 
identified by the UNIPROT accession number, were classified using 
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several parameters (e.g. functional annotation chart, KEGG analysis 
of pathways) to evaluate the possible role of the identified proteins 
in the HMGB1-interactome. Moreover, to confirm the proteomic 
results, data from microarray dataset of melanoma patients were 
analyzed through Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/gds ). 
 
STATISTICAL ANALYSIS 
 
All experiments were repeated three times, and the results are 
expressed as the mean ± SD (standard deviation) of three 
different determinations. Data were analyzed by the t-Student 
test, differences were considered highly significant when p<0.05 
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RESULTS 
GLYCATION OF BOVINE SERUM ALBUMIN 
 
Glycated-BSA (AGE-BSA) and non glycated BSA (BSA) were 
prepare under sterile conditions as above mentioned, and the AGE-
products have been characterized: AGE production was assessed 
by fluorescence and protein concentration by Bio-Rad protein 
assay.  
AGEs products are chemically heterogeneous, but out of ~80% are 
characterized by specific fluorescence, so that fluorescent AGEs 
could be measured by spectrofluorimetric analysis modified by 
Sampathkumar (Sampathkumar et al. 2005), which provides the 
measure of emission intensity at 430 nm, under excitation at 370 
nm. A single volume (80 μl) of samples of BSA and AGE-BSA 
incubated in vitro, was analyzed.  
The fluorescent AGE formation was related to the time of 
exposure to glycating sugar in a fluorescent measurements. 
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FIGURE 6: Fluorescent AGE levels (Arbitrary Unit/mg of 
proteins) in a BSA (4mg/ml) after 2, 4 and 8 weeks of 
incubation without D-glucose (BSA) and with a D-Glucose 500 
mM (BSA-AGE). Data are expressed as means ± SD. 
 
 
Preparations obtained with D-Glucose 500 mM for 8 weeks of 
incubation were found to have the greatest amount of fluorescent 
AGE and, for this reason, have been used for in vitro experiments. 
Further, glycated-BSA and BSA were also analyzed by size 
exclusion chromatography (FPLC), (FIGURE 7). 
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FIGURE 7: Chromatographic analysis of BSA and AGE-BSA 
   
The chromatographic profiles confirmed that AGE-BSA (i.e. BSA 
incubated with glucose) was really modified by the glucose 
treatment, leading to the formation of complexes with a larger 
molecular weight when compared to control BSA. 
 
CD26 INHIBITS HMGB1-INDUCED ENDOTHELIAL CELL 
MIGRATION 
 
CD26 is a 110-kDa cell surface glycoprotein which also exists as a 
soluble form circulating in plasma. CD26 selectively removes the N-
terminal dipeptides with either L-proline or L-alanine at the 
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penultimate position from a variety of chemokines, growth factors 
and neuropeptides. Proteolytic activity leads to inactivation or 
degradation of these peptides. Both glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) 
are endogenous physiological substrates for CD26, and chemical 
inhibition of CD26 activity, results in increased levels of intact 
bioactive GIP and GLP-1 and glucose tolerance. At present, CD26 
inhibitors are used as glucose-lowering agents in the treatment of 
type 2 diabetes (Dicembrini et al. 2011). 
Our data support recent observation from Takasawa showing that 
inhibition of CD26 enzymatic activity may affect endothelial cell 
functions including endothelial cell proliferation and ex vivo 
neovascularization following TNF-a or IL-1b stimulation (Takasawa 
et al. 2010).  
The impairment of angiogenesis in diabetes is well documented 
(Facchiano et al. 2006), however molecular defects involved in 
diabetes-related vascular defects so far have remained elusive and 
growth factor inactivation as well as increased production of 
angiogenesis inhibitors, may account for these defects.  
 51 
Migration is a key process required for angiogenesis and HMGB1 
display chemotactic activity on endothelial cells (Mitola et al. 
2006; Schlueter et al. 2005; De Mori et al. 2007). 
To investigate whether CD26 affected the HMGB1-mediated 
endothelial cell migration, the chetomotactic activity of intact and 
CD26-cleaved HMGB1 were compared in vitro on HUVEC cells. 
Since the structural analysis of HMGB1 suggest that it may contain 
potential CD26 cleavage sites we determined whether HMGB1 may 
be a substrate for CD26 and, eventually, whether CD26-mediated 
cleavage may alter its angiogenic activity (Marchetti et al. 2011).  
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FIGURE 8: Purified CD26 cleaves HMGB1.  
MALDI-TOF analysis of HMGB1. Upper pane: HMGB1 protein sequence. The red 
box indicates the peptide recognized by the indicated antibody. Lower panel: 
Western blot analysis of HMGB1 (5 µg) incubated with CD26 (0.5 µg) for the 
indicated time points. The same filter was probed with the anti-HMGB1 antibody 
that recognizes the N-terminal portion of the protein. 
 
 
THE EFFECTS OF AGE ON RAT RETINAS 
 
The ex vivo studies were performed on retinal tissue cultures 
explanted from adult rats and the in vitro studies were performed 
on retinal tissue. 
Retinal tissue were exposed for 6-48 hours to high glucose (HG) 
levels (30 mM D-glucose), to reproduce short term effects of 
elevated glucose concentrations, or in vitro glycated Bovine Serum 
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Albumin (BSA) (AGE-BSA: 200μg/ml), to reproduce long term 
effects of elevated glucose concentrations.  
Controls included 5.5 mM D-glucose, as normal glucose (NG) 
concentration, 30 mM D-mannitol (M) as an iso-osmotic control, and 
200μg/ml non-glycated BSA. At the end of the experimental 
procedures, tissue or cells were treated for protein analysis 
characterization.  
The retinal tissue were lysed and analyzed by western blot to study 
a modulation to the most important AGE receptor (RAGE) in a 
different conditions, previously described. 
Thirty μg of solubilized proteins were separated by 10% SDS-PAGE 
and transferred. The blot was incubated with anti-RAGE. 
The effects of 24-48 hours HG and AGE-BSA stimulation on RAGE 
expression in retinal explants are shown in FIGURE 9 showing a 
significant increase of RAGE expression upon these treatment, 
compared to controls. 
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FIGURE 9: Effects of AGE-BSA on RAGE levels in retinal 
explants. Rat retinal explants exposed to NG, HG, BSA and 
AGE-BSA for 24-48 h and analyzed by Western blot with rat 
anti-RAGE antibody. Solubilized proteins (30 μg) were separated 
by 10% SDS-PAGE. Identical samples were also run and probed 
with an anti-β-actin antibody to normalize the protein content.  
 
 
The same procedure was carried out to evaluate the TLR4 
expression under the same HG and AGE stimulations.  
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Even in these experiments, the TLR4 expression in lysates of 
retinal explants was significantly increased compared to control 
(BSA) (FIGURE 10). 
 
 
 
 
 
 
 
 
FIGURE 10: Effects of AGE-BSA on TLR4 levels in retinal 
explants. Rat retinal explants exposed to BSA and AGE-BSA 
for 24-48 h and analyzed by Western blot with rat anti-TLR4 
antibody. Identical samples were also run and probed with an 
anti-β-actin antibody to normalize the protein content 
 
 
To perform a proteomic evaluation of retinal tissues, 30 microgram 
of retinal tissue protein extracts were subjected to 4-15% gradient 
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SDS-PAGE analysis and then stained with Coomassie G-250 
BIORAD. 
The whole lane of each retinal lysate (both treated and untreated) 
was cut and digested with trypsin and the expressed proteome 
subsequently identified by LC-MS/MS. 
 
   
FIGURE 11: Mass spectrometry analysis of Retinal tissues; 
Normal Glucose, High Glucose, BSA and AGE (stimuli). 
 
Since retinal lysates did not allow to perform a high quality 
interactome analysis, due to the low amount of proteins analyzed 
and probably to some tissue degradation during retinal preparation, 
an additional model was analyzed, i.e. cell cultures.  
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HMGB1 IN HUVEC CELLS EXPOSED TO GLUCOSE AND 
AGE 
 
HUVEC were grown in the presence of BSA-AGE and AGE as 
described under Materials and Methods Section. 
 
            
FIGURE 12: Effects of BSA-AGE and AGE on HUVEC cells 
proliferation rate. Data are expressed as means ± SD. 
 
The HUVEC cell lysates were analyzed by immunoprecipitation to 
study the HMGB1 Interactome under our experimental condition 
and stumuli. 
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The IP was carried out using anti-HMGB1 antibody conjugated to 
protein A/G beads. 
 
 
FIGURE 13: Schematization of proteomics analysis 
 
The immunoprecipitated complex was then run on acrilammide 
gradient gel electrophoresis (SDS-PAGE) as described in Material 
and Methods. 
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To confirm the presence of HMGB1, the western blot was 
performed with anti-HMGB1 mouse monoclonal (FIGURE 14). 
 
 
                          
FIGURE 14: IP of HMGB1 using HUVEC cell lysates treated 
with (1) Normal Glucose, (2) High Glucose, (3) BSA, (4) AGE-
BSA. 
 
The increase of HMGB1 in total lysates with the different 
treatments was evaluated by western blot. 
As seen in FIGURE 15 the expression of HMGB1 in the cells 
treated with BSA-AGE is increased compared to its control BSA, 
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the same can be seen on the cells treated with high glucose 
compared to normal glucose. 
 
 
FIGURE 15: HUVEC cells with treatment with (1) Normal 
Glucose, (2) High Glucose, (3) BSA, (4) AGE-BSA, (5) High 
Mobility Group Box-1.  
 
The proteomic analysis of protein lysates from each treatment was 
then performed. 
The analysis was made on acrylamide gel stained with blue 
coomassie, each line was cut and digested with trypsin and 
subsequently analyzed with mass spectrometry. 
Thus, we have identified the proteomes of HUVEC treated with the 
stimuli under study and analysis led to the result reported in 
FIGURE 16.             
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FIGURE 16: HUVEC TREATED with Normal Glucose (CTRL), 
High Glucose (HG), mannitol isosmotic control (M), BSA AND 
AGE-BSA. Equal amount of proteins were loaded for each lane 
(35µg). 
 
HMGB1 IN A375 CELLS EXPOSED TO GLUCOSE AND AGE 
 
Another cell line, human melanoma A375 cells, were also exposed to 
the same hyperglycaemic and AGE stimuli, to study the HMBG1 
interactome. 
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The A375 cells were treated with AGE and its control BSA (see 
material and methods). 
The survival of melanoma cells treated with AGE compared to 
melanoma cells treated with BSA was unchanged, then the cell 
lysates were analyzed by immunoprecipitation to study the HMGB1 
interactome. 
 
FIGURE 17: a) A375 cells treated with BSA and b) A375 cells 
treated with AGE (400x). 
 
Some of the proteins identified in the total lysates treated (AGE) 
and their respective controls (BSA) by mass spectrometry were 
validated by bioinformatic analyses but further validation in ongoing 
by western blot.  
The amount of identified proteins with mass spectrometry are 
described in Table X analysis on cell lysated. 
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FIGURE 18: Proteomic analysis of A375 cell lines treatated 
with a BSA-AGE stimuli. 
 
 
AGE TREATMENT INDUCES INCREASE OF RAGE AND 
HMGB1: STUDY OF INTERACTOME 
 
The A375 cells were lysed and analazyed by western blot to study 
(see material and methods) a modulation of HMGB1 and RAGE 
proteins. The analysis of western blot on total lysates, showed a net 
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increase of HMGB1 in A375 cells treated with AGE compared to 
control (FIGURE 19). 
  
FIGURE 19: HMGB1 expression in a375 cell lysates after treatment 
with BSA or AGE-BSA. 
 
The analysis of western blot on total lysates, showed a increase too 
of RAGE in A375 cells treated with AGE compared to control 
(FIGURE 20).   
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FIGURE 20: RAGE expression in A375 cell lysates after 
treatment with bsa or AGE-BSA. 
 
THE AGE-INDUCED INTERACTOME TO HMGB1 
 
The A375 cells lysated were immunoprecipitated with anti-HMGB1 
antibody conjugated beads. A portion of the immunoprecipitated 
complexes (25% of the total sample) was electrophoretically 
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separated and transferred onto nitrocellulose while the remaining 
portion (75% of the total sample) was analyzed by LC-MS/MS. 
Western blot analysis of immunoprecipitated sample showed that 
AGE-treated cells express higher HMGB1 levels (FIGURE 21). 
 
                  
FIGURE 21: HMGB1 IP from A375 cells lysate.  
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FIGURE 22: Interactome analysis of IP-HMGB1 by Mass 
spectrometry analysis. 
 
PROTEIN ACCESSION NUMBER
1 DNJA2_ DnaJ homolog subfamily A member 2 O60884
2 MPPB_ Mitochondrial-processing peptidase subunit beta O75439
3 LEG1_ Galectin-1 P09382
4 HMGB1_ High mobility group protein B1 P09429
5 BTF3_ Transcription factor BTF3 P20290
6 PTBP1_ Polypyrimidine tract-binding protein 1 P26599
7 CTNA1_ Catenin alpha-1 P35221
8 oST48_ Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit P39656
9 EAA1_ Excitatory amino acid transporter 1 P43003
10 MSH2_ DNA mismatch repair protein Msh2 P43246
11 XPo2_ Exportin-2 P55060
12 DHSo_ Sorbitol dehydrogenase Q00796
13 PLoD1_ Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Q02809
14 MTX1_ Metaxin-1 Q13505
15 MoGS_ Mannosyl-oligosaccharide glucosidase Q13724
16 IDI1_ Isopentenyl-diphosphate Delta-isomerase 1 Q13907
17 ECM29_ Proteasome-associated protein ECM29 homolog Q5VYK3
18 PSMD1_ 26S proteasome non-ATPase regulatory subunit 1 Q99460
19 AN32E_ Acidic leucine-rich nuclear phosphoprotein 32 family member E Q9BTT0
20 PARP4_ Poly [ADP-ribose] polymerase 4 Q9UKK3
21 PSD13_ 26S proteasome non-ATPase regulatory subunit 13 Q9UNM6  
FIGURE 23: The analysis of the AGE-induced HMGB1 
interactome revealed the presence of 21 “unique” proteins, 
confirmed by two independent experimental sets. These proteins 
represent the AGEs-INDUCED HMGB1 INTERACTOME 
PROTEINS (AGHIPs). 
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DISCUSSION 
 
The principal aim of the present study is to elucidate the molecular 
mechanisms related to the inflammatory and angiogenic responses 
in human diseases like cancer and diabetes mellitus. In such 
diseases the alarmins are known to be key modulators of cellular 
response involved in the metabolic pathways of inflammation, but 
the molecular players involved are not yet completely understood.  
The specific aims of this PhD. Thesis have been focused on a) the 
development of a suitable experimental model, b) production and 
characterization of a molecular stimulus mimicking the 
inflammatory/hyperglycaemic stimulus and c); the study of the 
HMGB1-interactome, i.e. to identify proteins that interact with 
HMGB1, one of the most interesting alarmins.  
All the aims have been successfully carried out: In particular, a 
large amount of highly purified AGE-BSA was produced and 
characterized, by means of chromatographic analyses and 
functional assays. FPLC and spectrofluorescence analyses showed 
that AGE-BSA had higher molecular weight and fluorescence 
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behaviours characteristic of an AGE-modified protein, when 
compared to control BSA (FIGURES 6-7).  
Further, Multiplex measurements of cytokines (Bio-Plex assay) 
produced by cells exposed to this AGE-BSA showed an increased 
release of IL15, IL-2, MIP-1α and MIP-1β as expected when a pro-
inflammatory pathway is activated (Steel et al. 2011; De Rham 
et al. 2007; Coussens et al. 2002).  
This confirmed that the AGE-BSA stimulus was able to induce the 
pro-inflammatory pathways described in literature, but revealed 
also a number of interesting responses (e.g. modulation of IL-8 and 
MIP-proteins) which deserves to be further investigated. The 
efficacy of the AGE stimulus was also confirmed by western blot 
analyses showing an increased expression of RAGE and TLR4 when 
cells were exposed to AGE (FIGURES 9-10).  
Using the developed cellular model, i.e. A375 melanoma cells 
exposed to AGE-BSA, to be compared to BSA exposed A375 cells, 
the HMGB1 interactome was therefore analyzed by means of 
immunoprecipitation methods. The efficacy and reliability of this 
protocol was tested and confirmed by western blot and mass 
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spectrometry analyses of immunoprecipitated complexes (FIGURES 
21-22).  
The analysis of the AGE-induced HMGB1 interactome revealed the 
presence of 76 “unique” proteins, whose 21 proteins confirmed by 
two independent experimental sets. These proteins represent the 
AGEs-INDUCED HMGB1 INTERACTOME PROTEINS (AGHIPs) 
Interestingly, some of the identified AGHIPs, i.e. galectin and PARP 
have been reported to be significantly involved in cancer 
development and progression (Zhou X et al. 2011;  János 
Szebeni et al. 2012;) , confirming the efficacy of our 
experimental approach. 
In parallel experiments carried out by means of mass spectrometry 
analyses, the direct interaction of HMGB1 to CD26 has been 
demonstrated, indicating that the increased proteolytic activity in 
serum diabetic patients may contribute to the degradation and/or 
inactivation of soluble factors involved in angiogenesis. CD26 may 
play a pivotal role. Consistent with this hypothesis, CD26 levels 
increased in high glucose cultured microvascular endothelial cells as 
reported in a published manuscript (Marchetti et al. 2011). 
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The future plans of this study will be focused on the complete 
validation and functional characterization of the identified AGHIPs 
in order to identify novel molecular players of the vascular 
complications in DM and in angiogenic and inflammatory pathways 
regulation in melanoma patients.  
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